Trexquant Investment LP Prothena Corp Public LTD CO Transaction History

Trexquant Investment LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$32.31 - $52.32 $350,240 - $567,148	10,840 Added 19.07%	67,683 $2.46 Million
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $2.69 Million - $4.01 Million	56,843 New	56,843 $2.74 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $514,932 - $638,814	10,963 Added 35.1%	42,200 $2.05 Million
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $1.63 Million - $2.03 Million	31,237 New	31,237 $1.88 Million
Q1 2022 May 13, 2022	SELL	$30.27 - $49.22 $177,563 - $288,724	-5,866 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $247,017 - $429,743	5,866 New	5,866 $290,000
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $353,113 - $577,948	-7,326 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$21.63 - $57.65 $158,461 - $422,343	7,326 New	7,326 $377,000
Q4 2020 Feb 11, 2021	SELL	$10.12 - $13.94 $476,034 - $655,723	-47,039 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$9.93 - $13.47 $70,522 - $95,663	-7,102 Reduced 13.12%	47,039 $470,000
Q2 2020 Aug 07, 2020	BUY	$9.56 - $12.51 $517,587 - $677,303	54,141 New	54,141 $566,000
Q1 2019 May 13, 2019	SELL	$10.32 - $14.49 $202,860 - $284,829	-19,657 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$8.73 - $13.74 $29,175 - $45,919	-3,342 Reduced 14.53%	19,657 $202,000
Q3 2018 Nov 09, 2018	BUY	$12.7 - $15.79 $292,087 - $363,154	22,999 New	22,999 $301,000
Q2 2018 Aug 07, 2018	SELL	$10.99 - $44.21 $290,850 - $1.17 Million	-26,465 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$27.95 - $45.04 $739,696 - $1.19 Million	26,465 New	26,465 $972,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.